Cargando…

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer

Detalles Bibliográficos
Autores principales:	Nakamura, Kohei, Aimono, Eriko, Tanishima, Shigeki, Imai, Mitsuho, Nagatsuma, Akiko Kawano, Hayashi, Hideyuki, Yoshimura, Yuki, Nakayama, Kentaro, Kyo, Satoru, Nishihara, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446499/ https://www.ncbi.nlm.nih.gov/pubmed/32923896 http://dx.doi.org/10.1200/PO.19.00368

Ejemplares similares

Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma
por: Nakamura, Kohei, et al.
Publicado: (2020)

Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin’s glands reveals potential new routes for targeted therapies: a case report
por: Nakamura, Kohei, et al.
Publicado: (2020)

Genetic Profiling of Malignant Melanoma Arising from an Ovarian Mature Cystic Teratoma: A Case Report
por: Nakamura, Kohei, et al.
Publicado: (2021)

Clinical predominance of whole‐exome sequencing to evaluate microsatellite instability status
por: Takamatsu, Reika, et al.
Publicado: (2023)

Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors
por: Shimozaki, Keitaro, et al.
Publicado: (2021)

Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors
por: Saotome, Keiko, et al.
Publicado: (2020)

Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling
por: Ueki, Arisa, et al.
Publicado: (2021)

Estimating copy number using next-generation sequencing to determine ERBB2 amplification status
por: Nakamura, Kohei, et al.
Publicado: (2021)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

CRISPY-BRED and CRISPY-BRIP: efficient bacteriophage engineering
por: Wetzel, Katherine S., et al.
Publicado: (2021)

Reconstitution of high-grade serous ovarian carcinoma from primary fallopian tube secretory epithelial cells
por: Nakamura, Kohei, et al.
Publicado: (2017)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
por: Daimon, Tatsuaki, et al.
Publicado: (2021)

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations
por: Omura, Minami, et al.
Publicado: (2021)

High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients
por: Ishibashi, Tomoka, et al.
Publicado: (2019)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
por: Cheng, Yuan, et al.
Publicado: (2018)

CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
por: Yanai, Yoshinori, et al.
Publicado: (2020)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Tolerance of Olaparib in a Patient With Unresectable Serous Gynecologic Cancer and End-Stage Renal Disease
por: Goon, Kelsey C, et al.
Publicado: (2023)

The Case of an Endometrial Cancer Patient with Breast Cancer Who Has Achieved Long-Term Survival via Letrozole Monotherapy
por: Ishikawa, Masako, et al.
Publicado: (2023)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
por: Prete, Alessandra Anna, et al.
Publicado: (2022)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
por: Cao, Yabing, et al.
Publicado: (2019)

The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases
por: Nakamura, Kohei, et al.
Publicado: (2017)

Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer
por: Song, Honglin, et al.
Publicado: (2007)

Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies
por: Voutsadakis, Ioannis A
Publicado: (2020)

Two tSNPs in BRIP1 are associated with breast cancer during TDT analysis
por: Li, Xuefei, et al.
Publicado: (2021)

Hereditary Cancer Syndrome in a Family with Double Mutation in BRIP1 and MUTYH Genes
por: D’Elia, Giovanna, et al.
Publicado: (2023)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas
por: Machino, Hidenori, et al.
Publicado: (2023)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions
por: Nakamura, Kohei, et al.
Publicado: (2016)

Mutation profiles in circulating cell‐free DNA predict acquired resistance to olaparib in high‐grade serous ovarian carcinoma
por: Hu, Dianxing, et al.
Publicado: (2022)

A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
por: Kote-Jarai, Z, et al.
Publicado: (2009)

Loss of the BRCA1-Interacting Helicase BRIP1 Results in Abnormal Mammary Acinar Morphogenesis
por: Daino, Kazuhiro, et al.
Publicado: (2013)

BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity
por: ZOU, WEI, et al.
Publicado: (2016)

BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes
por: Gupta, Ishita, et al.
Publicado: (2017)

Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities
por: Kamal, Lara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6fel0mu2i2c3a5vlv92rjs092d